chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient had SHINGRIX vaccine 5 days ago, since then has been feeling tired, body aches, and redness and soreness to the injection site on left deltoid. This morning (6/29/18), started with itchy rash all over her body, scalp is itchy too. She has been on BACTRIM for 9 days for infected cyst. She doesn't remember if she has ever taken BACTRIM before as it has been years since taking any antibiotic. Denies sun exposure. Denies difficulty breathing, swelling to lips or throat, or dysphagia. Denies any new skin products. Denies fever or chills. Vitals: BP: 124/75, HR: 89, Temp: 98.1 degrees F, RR: 12. PE: General: WDWN, NAD. HENT: Head: Normocephalic, atraumatic. Ears: Canals clear. TMs pearly gray. Cone of light and bony landmarks visible. Eyes: Conjunctiva clear, sclera white bilaterally. Nose: Nares patent. Mucosa pink, moist. Turbinates without discharge or swelling. Oropharynx: Mucosa pink, moist without lesions. Pharynx pink; tonsils without hypertrophy or exudate. Resp: Nonlabored. Lungs clear to auscultation and with normal diaphragmatic excursion. No adventitious sounds. CVS: RRR. Normal S1, S2. No murmurs or extra heart sounds. NS: Erythemic macular rash from chest to legs. No rash on face, palms or pedal surfaces of feet. Left deltoid with same rash, mild tenderness to the deltoid. No urticaria. Assessment: Drug exanthem. Stop Bactrim. Short prednisone burst, daily cetirizine, BENADRYL 25-50 mg QHS. Encouraged use of daily fragrance-free lotion. Avoid bathing in hot water, use lukewarm water only. Expect can take up to 2 weeks to resolve. F/U if any worsening of rash or spreading of rash to palms or feet. ER precautions given for any symptoms of anaphylaxis. Adverse reaction to sulfa antibiotic. Sulfa added to allergy list. Adverse reaction to vaccine. Flu-like symptoms and pain and redness to injection site common side effects of SHINGRIX vaccine. Per CDC NOT a contraindication to receive 2nd dose. Plan: Tx: New PredniSONE 10 mg Tab Take 2 tabs orally daily for 2 days then 1 tab daily for 3 days #7 tablet RFx0.
Patient received COVID19 (Moderna) vaccine and reported nerve pain in injection arm following the injection. Patient stated that she was seen by a physician. Patient's physician will monitor for changes in condition and refer to a neurologist if symptoms worsen or do not improve.
Information has been received from a medical assistant concerning a male who on 25-OCT-2007 was vaccinated with zoster vaccine live (Oka/Merck). The patient, along with his wife (WAES# 0710USA05662) were scheduled to received zoster vaccine live (Oka/Merck) 25 Oct 2007. The medical assistant reported that during charting documentation, that same day, it was noted that only diluent was given to one of the patients, and the other patient received zoster vaccine live (Oka/Merck). The patient returned that same day and was re-vaccinated with zoster vaccine live (Oka/Merck) (lot 658209/1085U). The records were not available from the first lot number. Unspecified medical attention was sought. There was no product quality complaint. Additional information is not expected.
Day 3: Upset stomach, cramps, nausea, terrible headaches; Took Tylenol for headaches, didn?t help; lasting  3 days so far. Resting and praying symptoms will subside as I have had  some flu symptoms with ?Flu vaccine for over Age 65 patients previously, but never the Headaches before! Did not notify Doctor For the first 4 days.
This child appeared to have briefly loss consciousness and fell face down, striking her face on the floor; briefly following immunization. Hep A and Hep B (dose 1 each). Recovered spontaneously and by the time she was received in the ER, she was alert, talking, well oriented. The was no residual problem except redness, and swelling of the lip and the left eye from the impact on the floor. No confirmation of vaccine reaction received by the parent.
Fatigue, swelling and tenderness at injection site.  Red swelling 2 inches across and 1.5 inches wide.  Painful enough to wake me in the night.  Some relief from Tylenol.
Mother notified us at 16:15, that by 12:15 pt had a fever of 101 (ax). Pt also had dry heaves. Pt was taken to ER. In ER pt's temperature was 103.7F (rectal), pulse was ^200 and pt had increased respirations. There was no swelling, redness, itching or tenderness at vax site. MD felt pt was having an allergic reaction to the varicella vaccine. Pt had no symptoms of respiratory distress. Pt was given Motrin, Tylenol and Benadryl in ER and was told to continue with this regimen throughout the day. Pt's temperature decreased within 2 hours of medications and pt has a follow-up appt for 8/10/00. Follow-up doctor stated pt was afebrile and no abnormalties were seen on exam. He did feel pt could be having a reaction to a viral infection opposed to a vaccine reaction.
So i received my last booster on November 15.2021 at pharmacy inside the store. On Monday May 9th, I woke with a scratchy throat t that lasted until Wednesday May 11. On Thursday May 12, I woke up with a productive cough. I went to work. Later during the day I developed a fever of 100. on the back it was 102. I left work as soon as I could. I went to urgent care . I did a rapid test which came back positive! the nurse there gave me Benzonate pearls for the cough. I had some chills. The highest my fever got after getting the positive test results was 102.2. I had an on and off headache which seemed to help with Dayquil. I had an on and off stuffy nose and then I lost my taste and smell. On 5/16 I pretty much got my smell and my taste back. I just smell a smell like when your sick. Today 5/17 my smell and taste are okay I just smell the smell you usually smell when you have a cold. I am going to get retested with a rapid test today at 12:30 PM
Pt. received MENVEO IM injection at 11:35 on 6/22/12. Became light-headed at 11:40 while getting ready to leave health dept. with her mom. Had her lay down with cool cloth to forehead. Offered water/crackers when feeling better. VS as follows = 112/66, P = 48. Left health dept. at 11:55 feeling better with VS as follows = 99/63, P = 59.
Pt has history of nearly continual shingles outbreaks prior to vaccination. Pt was not experiencing shingles at the time of vaccination. Pt started feeling new outbreak 1-6-12 - pain in lower back, hips, buttocks & groin radiating to front of groin. Rash appeared 1-8-12. Pt reported this outbreak was more severe in pain and lasted twice as long as normal outbreaks. Normal outbreaks were lasting 1 week and this one lasted 2 weeks. However, no further severe outbreaks have occurred & frequency of normal outbreaks has decreased (she has a couple weeks without outbreaks now.).
myalgias; fever; headache; nausea; This is a spontaneous report from a contactable consumer. A 32-year-old male patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EK9231), via an unspecified route of administration (left arm) on 08Jan2021 (12:00 PM) at single dose for Covid-19 immunization. The patient's medical history reported as none; no known allergies. Concomitant medications were not reported. The patient previously received the first dose of BNT162B2 via an unspecified route of administration (left arm) on 18Dec2020. The patient was not diagnosed with COVID-19 prior to vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. It was reported that the day after the 2nd injection 09Jan2021, the patient had myalgias, fever, headache and nausea. It had mostly resolved on the following day 10Jan2021 and completely resolved on 11Jan2021. The patient took Tylenol and Advil as treatment. The outcome of events was recovered on 11Jan2021. The patient has not been tested for COVID-19 since the vaccination.
tingling rash; itching; Tingling rash; This case was reported by a nurse via call center representative and described the occurrence of tingling in a 91-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 28th May 2019, the patient received the 2nd dose of Shingrix (intramuscular) .5 ml. On 28th May 2019, less than a day after receiving Shingrix, the patient experienced tingling, pruritus and rash. On an unknown date, the outcome of the tingling, pruritus and rash were unknown.   It was unknown if the reporter considered the tingling, pruritus and rash to be related to Shingrix.  Additional information was provided as follows: The patient received Shingrix on the right arm. The patient experienced itching, tingling rash on her back in the bra area underneath her shoulder blades. The rash was noticed the evening of 2nd June 2019 and it had gotten worse. The tingling was described as occurring intermittently, and the itching described as occurring once in a while. The reporters main question for calling was to ask what was the likelihood of Shingrix causing shingles.
This is a spontaneous report from a contactable physician received via a Pfizer sales representative. A male patient of an unspecified age received TRUMENBA, via an unspecified route of administration on an unspecified date at a single dose for immunization. The patient's medical history and concomitant medications were not reported. The patient experienced severe swelling on arm after receiving TRUMENBA. He did not require further treatment. The outcome of the event was unknown.
Localized red rash/indurations to left thigh measuring 10 x 15 cm.
Shortly after receiving flu vaccine patient started with hives to neck chest and left arm, shaking, and feeling flushed. Pt transported to ED 0800, she received 50mg diphenhydramine, 20mg famotidine, and 80 methylprednisolone IV push. Pt had resolution of symptoms and was discharged home.
March 20,2021, horizontal double vision upon awakening lasting 40 minutes Mrch 22, 2021, horizontal double vision upon awakiening lasting five minutes.  (I also experienced double vision following the first dose and filed a VAERS.  I had two episodes of double vision following by third dose and will file another VAERS.)
Patient left vaccination site after waiting 15 minutes post vaccination. Approximately 15-20 minutes later she experienced facial flushing, tingling and "itchy throat" confined to her face and neck. She returned to the vaccination site, was seated, and assessed. She denied symptoms of shortness of breath or swelling of the throat or tongue. Her radial pulse was steady and regular at 80 BPM. She denied sx of tachycardia, orthostasis. There was no audible stridor. Her BP was measured at 125/70 mm Hg. She was treated with 12.5mg of liquid diphenhydramine. This dose was repeated approximately 20 minutes later since her sx did not improve. The patient was given bottled water and consumed  approx 16 oz over the course of 30min. She was also given a cold wet face cloth for symptomatic relief of the flushing. The patient got up X2  to use the restroom w/o event - denied dizziness or orthostasis. After approx. 50 min the pt  was determined to be stable and contacted a family member to drive her home. She left the clinic without incident.
~6 hours post vaccine started to have fatigue, chills, and general body weakness, then headache started too
This case was reported by a other health professional and described the occurrence of erythema in a 11-year-old female patient who received MENVEO (batch number A16093, expiry date March 2018). On 6th February 2017, the patient received MENVEO (intramuscular). On an unknown date, less than a year after receiving MENVEO, the patient experienced erythema and swelling arm. On an unknown date, the outcome of the erythema and swelling arm were recovered/resolved. It was unknown if the reporter considered the erythema and swelling arm to be related to MENVEO. Additional details were reported as follows: The patient experienced redness in arm and swelling (9 x 6 cm) raised area, lasting for 2 days.
This case was reported by a consumer via call center representative and described the occurrence of injection site swelling in a male patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced injection site swelling, injection site bruising and poor sleep. On an unknown date, the outcome of the injection site swelling, injection site bruising and poor sleep were unknown. It was unknown if the reporter considered the injection site swelling, injection site bruising and poor sleep to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. Two and a half months prior to the second dose, the patient received 1st dose of SHINGRIX on left arm. The patient experienced bruising and not sleeping well at night. The patient said that he had a bruise and swelling at the injection site on his left arm. The patient said that the bruise and swelling was about the size of a baseball. For tolerance of 2nd dose of SHINGRIX refer linked case US2018127891.
9AUG92 mild fever, pallor, staring episodes x 2 lasting about a minute; occurred w/in 24 hrs of vax but had similar episode in MAY;
Acute Lymphadenopathy High Bp Rash PVC's   Went to see PCP , Cardiology, Endo, ENT . 6 months later Lymphnodes still swollen and diagnosted with auto immune (Hashimotos)
Pt called to report that 24 hrs after receiving TD injection, she developed swelling, raised rash, itch/pruritis, redness and pain at injection site. Symptoms were ongoing for more than 3 weeks. Pt reports 32 days after symptoms presented, she sough medical care for pain. Received prescription for ibuprofen per pt report.
1st dose on 1-MAR-2022. 2nd dose was today 1-NOV; This case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 56-year-old male patient who received HAB (Twinrix) (batch number 2ke55, expiry date 22nd September 2023) for prophylaxis.   Co-suspect products included hepatitis A and hepatitis B vaccine pre-filled syringe device (Twinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   Previously administered products included Twinrix (received 1st dose on 1st March 2022).   On 1st November 2022, the patient received the 2nd dose of Twinrix and Twinrix Pre-Filled Syringe Device. On 1st November 2022, unknown after receiving Twinrix and Twinrix Pre-Filled Syringe Device, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 01-NOV-2022 Reporter's comment: The pharmacist reported that the patient received second dose of Twinrix today (on the day of reporting). The expiration date was from salesforce. The reporter did not consent to follow up. Additional Supportive Information: The patient received the second dose of Twinrix later than the recommended interval, which led to lengthening of vaccination schedule.
Six days later, itching that progressed to raised, red patch about 3" by 1.5".  Harmless from what I can read, seems to be classic Moderna arm, only researched it because it happened almost a week after the injection. Thought it might be helpful information in the data base.
mom noticed an area beside the place of inj being hard & red;area 2in by 1in;pt had no fever-some pain;mom brought pt to MD that felt pt was reacting to the tetanus;no tx just APAP
High fever to 103F. Muscle weakness and pain (generalized) w/ assoc difficulty walking.
Nausea; Vomiting; This spontaneous case was reported by a consumer and describes the occurrence of NAUSEA (Nausea) and VOMITING (Vomiting) in a 20-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced NAUSEA (Nausea) and VOMITING (Vomiting). At the time of the report, NAUSEA (Nausea) and VOMITING (Vomiting) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication reported. No treatment information provided.
Extreme pain in vertebrae from March to June 2021.  Spinal infection in vertebrae leading to staph infection June 6, 2022.  Remaining on antibiodics as  of this date.
headache, severe joint pain, chest pain. headache lasted a couple months. i don?t feel the joint pain has ever fully gone away. the chest pain lasted 4 to 6 weeks and i often wonder if it damaged my heart. so i decided to finally report this in case i have heart problems in the future.
IPV VACCINE GIVEN AFTER EXPIRATION DAY  IPV GIVEN 10/12/2022 VACCINE EXPIRED 10/10/2022
Numbness from September 11th early in the morning to September 12 a full 24 hours later.
Site: Itching at Injection Site-Mild, Systemic: pt had tingling on left side of face from lips to ear and arm felt funny
Redness and swelling on left arm.  According to patient, the left arm appears red, warm, and slight swelling compare to the right arm
It was reported that a 25 year old female patient was immunized 11/25/01 at 1:30 pm with a Fluzone SV '01-'02 vaccine. That same day, the patient developed hives on her legs at 3:30 pm. She was seen in employee health clinic and treated with Benadryl.  Patient was seen on Nov 27th by medical manger-hives still present. First time receiving flu vaccine for the patient. Prior allergies reaction to Augmentin.
Patient is currently in a long term care facility that had a Moderna Vaccination clinic on 2/11/2021. The staff said the vaccine would be the first dose for the patient and a COVID vaccination card was created. After returning from the clinic the Walgreens staff enters in the prescriptions and scans in VARs. Upon a compliance report stating the vaccine was the patient's second dose and not the first. Upon looking at the patient's central profile it was determined that the patient did receive a dose of Pfizers vaccine 1/25/2021. The facility the patient resides in was called and was informed. They stated they had no documentation or paperwork from the patient's previous facility informing of the covid vaccination. The DON said the patient was not experiencing any issues.  So the patient received Pfizer on 1/25 and then the moderna on 2/11.
Immediately after Menactra vaccine administration, patient felt dizzy and almost passed out and escorted to lay down. Patient reports that she has not recollection of events after vaccine being administered until when she saw herself on the floor. No seizure or seizure like activity reported. Blood pressure in the 70's during recovery.  Patient was referred to ER for further management.
4 hours after getting Fluad vaccination, I started shaking badly and had the chills.  This lasted for 4 hours, then I went to bed.  The next day 10/26/22 I felt fine.  This year 11/3/2023, I got the Fluzone High-Dose Quadrivalent and was perfectly fine (over many many past years I have received this influenza vaccine and have always been fine)
pt presents to ED with c/o increasing SOB (over past week) and chest pain; diagnosed positive for COVID 5 days prior; treated with remedesivir, baricitinib, steroids, O2 supplementation, antibiotics; pneumonia due to COVID, sepsis; while in hospital experienced pulseless electrical activity, ACLS protocol followed, obtained ROSC; pt intubated and on mechanical ventilation; pt's condition worsened, poor prognosis; comfort measures and pt extubated; he died in the hospital
positive for COVID; positive for COVID; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "positive for COVID". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: positive. Therapeutic measures were taken as a result of drug ineffective, covid-19. The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5, BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-PV202300057980 same reporter product event, different patient;
This spontaneous report as received from a medical assistant refers to a 9 month old patient of unknown gender. The concurrent conditions, drug reactions/allergies and medical history of the patient were not reported. On 29-NOV-2016, the patient was vaccinated with a dose of improperly stored RECOMBIVAX with lot number M032649 and expiration date of 11-NOV-2018 (strength, dose, route of administration and anatomical location were unknown) for prophylaxis, which was stored at 1.1 Celsius degrees (°C) for 27 minutes, 0.7 °C for 19 minutes, 1.1 °C for 36 minutes, 0.7 °C for 29 minutes, 1.3 °C for 17 minutes, 1.1 °C for 20 minutes, 0.9 °C for 26 minutes, 0.7 °C for 31 minutes and 1.2 °C for 24 minutes. There was no previous temperature excursion. Moreover, the temperature excursions were detected by a data logger. No concomitant therapies nor adverse effects were reported. No product quality complaint was involved.  This is one of several cases from the same reporter. Additional information has been requested.; Sender's Comments: US-009507513-1701USA007921: US-009507513-1701USA007910: US-009507513-1701USA004148: US-009507513-1701USA003168: Original Case : 1701USA004148 US-009507513-1701USA007912:Original Case : 1701USA004148 US-009507513-1701USA007922: US-009507513-1701USA007881: US-009507513-1701USA007913: US-009507513-1701USA004150: US-009507513-1701USA007958: US-009507513-1701USA007906: US-009507513-1701USA007895: US-009507513-1701USA007896: US-009507513-1701USA007923: US-009507513-1701USA004152: US-009507513-1701USA007883: US-009507513-1701USA007897: US-009507513-1701USA007905: US-009507513-1701USA007884: US-009507513-1701USA007924: US-009507513-1701USA007925: US-009507513-1701USA007847: US-009507513-1701USA007885: US-009507513-1701USA007908: US-009507513-1701USA007909: US-009507513-1701USA007898: US-009507513-1701USA007914: US-009507513-1701USA007915: US-009507513-1701USA007916: US-009507513-1701USA007848: US-009507513-1701USA007849:
Temp 100.5 -  Chills (strong)  - Muscles & joints hurt - Lethargic - Felt like having the Flu.  Soreness around injection area - Took Tylenol - As of this writing (01/24/21) I feel a lot better. I have not contacted my Dr. I will do so tomorrow.
started to have a headache the day after the shoot, tried to sleep it off. Had chills and felt slightly weak. Went away after the day after the side affects.
Information has been received from a nurse concerning a 26 year old female who was vaccinated with the second dose of GARDASIL.  Subsequently the patient developed angioendemic urticaria.  At the time of this report, the outcome was unknown.  No product quality complaint was unknown.  Additional information has been requested.